Sugi Predict

Sugi Predict / Compounds / SCHEMBL8689191

SCHEMBL8689191

SCHEMBL8689191

CCCN(CCC)C1Cc2ccc(C)cc2C1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD3 P35462 8/20 0.66
▸ FYN P06241 1/20 0.62
▸ CYP2D6 P10635 2/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ DRD2 P14416 7/20 0.54
▸ DRD4 P21917 4/20 0.54
▸ HTR1A P08908 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ADRB2 P07550 1/20 0.54
▸ CASP1 P29466 1/20 0.54
▸ LMNA P02545 2/20 0.52
▸ MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17446285 0.87 DRD2 (0.72) DRD3FYNCYP2D6DRD2DRD4
SCHEMBL8693035 0.82 FYN (0.70) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL6560127 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL7854684 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL8689650 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL8689229 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL7854718 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL7449385 0.81 DRD3 (0.78) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL8689268 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9
SCHEMBL7861296 0.81 DRD3 (0.64) DRD3FYNCYP2D6ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024062395-A1 USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME Clearmind Medicine Inc. (IL) 2024-03-28 — — WO disclosed
CN-112500301-B Regulator for longitudinal behavior 以西结·戈兰 2024-02-13 — — CN disclosed
US-20230092839-A1 ALCOHOLIC BEVERAGE SUBSTITUTES Clearmind Medicine Inc. (CA) 2023-03-23 — — US disclosed
US-11528924-B2 Alcoholic beverage substitutes Clearmind Medicine, Inc. (CA) 2022-12-20 — — US disclosed
CN-114903134-A Alcoholic beverage substitute 以西结·戈兰 2022-08-16 — — CN disclosed
CN-114403335-A Alcoholic beverage substitute 以西结·戈兰 2022-04-29 — — CN disclosed
US-20210330607-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2021-10-28 — — US disclosed
US-20210330608-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2021-10-28 — — US disclosed
US-20210330609-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2021-10-28 — — US disclosed
US-11077072-B2 Binge behavior regulators Clearmind Medicine Inc. 2021-08-03 — — US disclosed
US-10137096-B2 Binge behavior regulators CLEARMIND LABS CORP. (CA) 2018-11-27 — — US disclosed
US-20180085326-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2018-03-29 — — US disclosed
US-20170360067-A1 ALCOHOLIC BEVERAGE SUBSTITUTES CLEARMIND LABS CORP. (CA) 2017-12-21 — — US disclosed
EP-3230256-A1 ALCOHOLIC BEVERAGE SUBSTITUTES Golan, Ezekiel (CA) 2017-10-18 — — EP disclosed
EP-3230255-A1 BINGE BEHAVIOR REGULATORS Golan, Ezekiel (CA) 2017-10-18 — — EP disclosed
WO-2016092547-A1 ALCOHOLIC BEVERAGE SUBSTITUTES GOLAN EZEKIEL (IL) 2016-06-16 — — WO disclosed
WO-2016092546-A1 BINGE BEHAVIOR REGULATORS GOLAN EZEKIEL (IL) 2016-06-16 — — WO disclosed
US-5708018-A 2-aminoindans as selective dopamine D3 ligands PHARMACIA & UPJOHN COMPANY (US) 1998-01-13 — — US disclosed
EP-0712387-A1 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1996-05-22 — — EP disclosed
WO-1995004713-A1 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS THE UPJOHN COMPANY (US) 1995-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180085326-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD3 131/4885FYN 4855/4885CYP2D6 2059/4885
US-20230092839-A1 ALCOHOLIC BEVERAGE SUBSTITUTES ADH1A, ADH5, ADH1C DRD3 431/4885FYN 3559/4885CYP2D6 1235/4885
US-10137096-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DRD3 131/4885FYN 4855/4885CYP2D6 2059/4885
US-11077072-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DRD3 131/4885FYN 4855/4885CYP2D6 2059/4885
US-20210330609-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD3 131/4885FYN 4855/4885CYP2D6 2059/4885
US-11528924-B2 Alcoholic beverage substitutes ADH1A, ADH5, ADH1C DRD3 431/4885FYN 3559/4885CYP2D6 1235/4885
US-20210330607-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD3 131/4885FYN 4855/4885CYP2D6 2059/4885
US-20210330608-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD3 131/4885FYN 4855/4885CYP2D6 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.